TG Therapeutics, Inc.

Contributing Author

Recent Articles by TG Therapeutics, Inc.

May-06	TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance TGTX +16.26% GlobeNewswire
Apr-30	TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update TGTX GlobeNewswire
Apr-22	TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting TGTX +5.60% GlobeNewswire
Apr-15	TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI TGTX GlobeNewswire
Mar-19	TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million TGTX GlobeNewswire
Mar-09	Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI in People with Highly Active Relapsing Multiple Sclerosis TGTX GlobeNewswire
Mar-06	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting TGTX GlobeNewswire
Feb-26	TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance TGTX GlobeNewswire
Feb-23	TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update TGTX GlobeNewswire
Feb-17	Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis TGTX GlobeNewswire
Feb-08	TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis TGTX GlobeNewswire
Feb-06	TG Therapeutics Announces Presentation of Data for BRIUMVI (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum TGTX GlobeNewswire
Jan-27	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum TGTX GlobeNewswire
Jan-13	TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones TGTX +5.99% TGTX GlobeNewswire
Jan-07	TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference TGTX GlobeNewswire
Nov-28	TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference TGTX GlobeNewswire
Nov-19	TG Therapeutics Makes 2025 Deloitte Technology Fast 500 List of America's Fastest-Growing Companies TGTX GlobeNewswire
Nov-10	TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit TGTX -6.02% GlobeNewswire
Nov-03	TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance TGTX GlobeNewswire
Oct-31	TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update TGTX GlobeNewswire
Oct-28	TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI TGTX GlobeNewswire
Sep-24	New Data for BRIUMVI Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment TGTX GlobeNewswire
Sep-10	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting TGTX GlobeNewswire
Sep-08	TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment TGTX GlobeNewswire
Sep-04	TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference TGTX GlobeNewswire
Sep-03	TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program TGTX +6.66% GlobeNewswire
Aug-28	TG Therapeutics to Participate in the Cantor Global Healthcare Conference TGTX GlobeNewswire
Aug-04	TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance TGTX -17.99% GlobeNewswire
Jul-30	TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update TGTX GlobeNewswire
Jun-06	TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference TGTX GlobeNewswire
Jun-02	TG Therapeutics to Participate in the Jefferies Global Healthcare Conference TGTX GlobeNewswire
May-30	TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting TGTX GlobeNewswire
May-27	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting TGTX GlobeNewswire
May-05	TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance TGTX -13.26% GlobeNewswire

TG Therapeutics, Inc.

Recent Articles by TG Therapeutics, Inc.

Upgrade your Finviz experience